Position in NVS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$82,132,720
-$18,215 QoQ
Shares Held
524,073
-2.6% QoQ
Ownership
0.028%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#42
of 1,603 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 99%
Shared 0%
None 1%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026CIBC Bancorp USA Inc. holds $3,129,371,757 across 13 Drug Manufacturers - General names. NVS ranks #7 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
906,485 | $1,087,265,393 | |
| 2 | AZN |
Astrazeneca PLC
|
3,772,997 | $715,435,690 | |
| 3 | ABBV |
AbbVie Inc.
|
1,860,030 | $468,057,948 | |
| 4 | JNJ |
Johnson & Johnson
|
1,352,624 | $343,525,915 | |
| 5 | AMGN |
Amgen Inc
|
529,613 | $191,783,459 | |
| 6 | MRK |
Merck & Co., Inc.
|
917,223 | $117,863,154 | |
| 7 | NVS |
Novartis AG
This page
|
524,073 | $82,132,720 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
351,087 | $44,356,330 |
All Filings in NVS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $82,132,720 | 524,073 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $82,150,935 | 537,813 | Shares | Defined | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||